| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Increases 2026 Revenue Guidance to a Range of $115 million to $117 million |
| 14 Aug 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1 Registered Office. The registered office of Delcath Systems, Inc. (the “Corporation”) in the State of Delaware and the name of the Corporation’s registered agent at such address shall be as set forth in the certificate of inc... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Increases 2026 Revenue Guidance to a Range of $104M to $108M |
| 14 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – May 7, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the fi... |
| 03 Mar 2026 |
8-K: Other Events
QUEENSBURY, NY – March 3, 2026 Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – February 26, 2026, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial r... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Exhibit 99.2 Corporate Presentation NASDAQ: DCTH January 9, 2026 |
| 20 Nov 2025 |
8-K: Other Events
On November 19, 2025, the board of directors of Delcath Systems, Inc., a Delaware corporation (the “Company”) authorized a share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of com... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – November 4, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results ... |
| 20 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
QUEENSBURY, N.Y.—(BUSINESS WIRE)—Oct. 18, 2025— Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomiz... |
| 15 Aug 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1 Registered Office. The registered office of Delcath Systems, Inc. (the “Corporation”) in the State of Delaware and the name of the Corporation’s registered agent at such address shall be as set forth in the certificate of inc... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – August 6, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results an... |
| 22 May 2025 |
8-K: Regulation FD Disclosure; Other Events
QUEENSBURY, NY – May 22, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financi... |
| 16 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – May 8, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and b... |
| 21 Mar 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by Delcath Systems, Inc. under Item 4.01 of its Form 8-K dated March 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other s... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
QUEENSBURY, NY – March 6, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial resul... |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Exhibit 99.2 Corporate Presentation NASDAQ: DCTH January 2025 |
| 30 Dec 2024 |
8-K: Regulation FD Disclosure; Other Events
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se... |
Loading...